Dare Bioscience Inc (NASDAQ:DARE) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Saturday.

WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this article can be accessed at https://www.americanbankingnews.com/2017/07/22/dare-bioscience-inc-nasdaqdare-upgraded-at-valuengine.html.

About Dare Bioscience

Dare Bioscience, Inc, formerly Cerulean Pharma Inc, is a healthcare company. The Company is focused on the development and commercialization of products in women’s reproductive health. Its lead product candidate is Ovaprene, a clinical stage, non-hormonal contraceptive ring. The Company is developing Ovaprene to provide protection over multiple weeks of use and require no intervention at the time of intercourse.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Dare Bioscience (NASDAQ:DARE)

Receive News & Ratings for Dare Bioscience Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dare Bioscience Inc and related companies with MarketBeat.com's FREE daily email newsletter.